# A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer

> **NCT04608786** · PHASE1 · UNKNOWN · sponsor: **Lee's Pharmaceutical Limited** · enrollment: 10 (estimated)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** ZKAB001 5mg/kg
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04608786
- **Lead sponsor:** Lee's Pharmaceutical Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04608786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04608786, "A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04608786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*